{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T14:28:15Z","timestamp":1782570495679,"version":"3.54.5"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.bcmd.2017.04.008","type":"journal-article","created":{"date-parts":[[2017,5,2]],"date-time":"2017-05-02T12:19:11Z","timestamp":1493727551000},"page":"38-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Resolution of a steroid-resistant, hypereosinophilic immune diathesis with mepolizumab and concomitant amelioration of a mixed thrombotic microangiopathy"],"prefix":"10.1016","volume":"69","author":[{"given":"J. Justin","family":"Mulvey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Magro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Chadburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2017.04.008_bb0005","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0065-2776(08)01003-1","article-title":"Biology of the eosinophil","volume":"101","author":"Blanchard","year":"2009","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.bcmd.2017.04.008_bb0010","series-title":"Middleton's Allergy Principles and Practice","author":"Franklin Adkinson","year":"2014"},{"key":"10.1016\/j.bcmd.2017.04.008_bb0015","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1365-2222.2008.02958.x","article-title":"Eosinophils: biological properties and role in health and disease","volume":"38","author":"Hogan","year":"2008","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.bcmd.2017.04.008_bb0020","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1084\/jem.172.4.1271","article-title":"Activation of platelets by eosinophil granule proteins","volume":"172","author":"Rohrbach","year":"1990","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bcmd.2017.04.008_bb0025","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/j.1365-2141.1995.tb05211.x","article-title":"Major basic protein binding to thrombomodulin potentially contributes to the thrombosis in patients with eosinophilia","volume":"90","author":"Mukai","year":"1995","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2017.04.008_bb0030","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/BF00641316","article-title":"Thromboembolism in a patient with transient eosinophilia","volume":"72","author":"Yamamoto Mukai","year":"1996","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.bcmd.2017.04.008_bb0035","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1172\/JCI116382","article-title":"Eosinophil cationic granule proteins impair thrombomodulin function: a potential mechanism for thromboembolism in hypereosinophilic heart disease","volume":"91","author":"Slungaard","year":"1993","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcmd.2017.04.008_bb0040","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2005-05-2152","article-title":"The principal eosinophil peroxidase product, HOSCN, is a uniquely potent phagocyte oxidant inducer of endothelial cell tissue factor activity: a potential mechanism for thrombosis in eosinophilic inflammatory states","volume":"107","author":"Wang","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2017.04.008_bb0045","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/0049-3848(79)90119-1","article-title":"Enhancement of factor XII dependent reactions by eosinophil cationic protein","volume":"14","author":"Venge","year":"1979","journal-title":"Thromb. Res."},{"key":"10.1016\/j.bcmd.2017.04.008_bb0050","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/ijlh.12057","article-title":"Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: a review","volume":"35","author":"Savage","year":"2013","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/j.bcmd.2017.04.008_bb0055","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.jaci.2006.02.042","article-title":"Workshop summary approaches to the treatment of hypereosinophilic syndromes: a workshop summary report","volume":"117","author":"Klion","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.bcmd.2017.04.008_bb0060","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.mpdhp.2009.01.012","article-title":"Bone marrow disorders with associated eosinophilia","volume":"15","author":"Rodig","year":"2009","journal-title":"Diagn. Histopathol."},{"key":"10.1016\/j.bcmd.2017.04.008_bb0065","series-title":"Growth Factors and Cytokines in Health and Disease","author":"Delany","year":"1997"},{"key":"10.1016\/j.bcmd.2017.04.008_bb0070","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1074-7613(00)80294-0","article-title":"IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses","volume":"4","author":"Kopf","year":"1996","journal-title":"Immunity"},{"key":"10.1016\/j.bcmd.2017.04.008_bb0075","doi-asserted-by":"crossref","first-page":"4544","DOI":"10.4049\/jimmunol.165.8.4544","article-title":"Role of IL-5 in innate and adaptive immunity to larval Strongyloides stercoralis in mice","volume":"165","author":"Herbert","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcmd.2017.04.008_bb0080","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa070812","article-title":"Treatment of patients with the hypereosinophilic syndrome with Mepolizumab","volume":"358","author":"Rothenberg","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2017.04.008_bb0085","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2017.04.008_bb0090","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1084\/jem.173.2.429","article-title":"Transgenic mice expressing a B cell growth and differentiation factor gene (interleukin 5) develop eosinophilia and autoantibody production","volume":"173","author":"Tominaga","year":"1991","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bcmd.2017.04.008_bb0095","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.4049\/jimmunol.158.3.1332","article-title":"Expression of IL-5 in thymocytes\/T cells leads to the development of a massive eosinophilia, extramedullary eosinophilopoiesis, and unique histopathologies","volume":"158","author":"Lee","year":"1997","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcmd.2017.04.008_bb0100","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/icb.2008.72","article-title":"IL-5-overexpressing mice exhibit eosinophilia and altered wound healing through mechanisms involving prolonged inflammation","volume":"87","author":"Leitch","year":"2009","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.bcmd.2017.04.008_bb0105","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/intimm\/dxp102","article-title":"IL-5- and eosinophil-mediated inflammation: from discovery to therapy","volume":"21","author":"Kouro","year":"2009","journal-title":"Int. Immunol."},{"key":"10.1016\/j.bcmd.2017.04.008_bb0110","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.jaci.2007.03.048","article-title":"Eosinophil trafficking in allergy and asthma","volume":"119","author":"Rosenberg","year":"2007","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.bcmd.2017.04.008_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2009.11.017","article-title":"IgE, mast cells, basophils, and eosinophils","volume":"125","author":"Stone","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.bcmd.2017.04.008_bb0120","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.intimp.2007.07.006","article-title":"The role of the complement anaphylatoxins in the recruitment of eosinophils","volume":"7","author":"DiScipio","year":"2007","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bcmd.2017.04.008_bb0125","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.4049\/jimmunol.162.2.1127","article-title":"A comparison of C3a and C5a-mediated stable adhesion of rolling eosinophils in postcapillary venules and transendothelial migration in vitro and in vivo","volume":"162","author":"DiScipio","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcmd.2017.04.008_bb0130","doi-asserted-by":"crossref","DOI":"10.1084\/jem.181.6.2119","article-title":"C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation","volume":"181","author":"Daffern","year":"1995","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bcmd.2017.04.008_bb0135","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.intimp.2014.05.008","article-title":"Treatment with the C5a receptor\/CD88 antagonist PMX205 reduces inflammation in a murine model of allergic asthma","volume":"21","author":"Staab","year":"2014","journal-title":"Int. Immunopharmacol."},{"issue":"Suppl","key":"10.1016\/j.bcmd.2017.04.008_bb0140","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000236743","article-title":"Degranulation from human eosinophils stimulated with C3a and C5a","volume":"104","author":"Takafuji","year":"1994","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.bcmd.2017.04.008_bb0145","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/WOX.0b013e31817a76fb","article-title":"Basophils as key regulators of allergic inflammation and Th2-type immunity","volume":"1","author":"Gibbs","year":"2008","journal-title":"World Allergy Organ. J."},{"key":"10.1016\/j.bcmd.2017.04.008_bb0150","first-page":"32","article-title":"Interleukin-5 induces maturation but not class switching of surface IgA-positive B cells into IgA-secreting cells","volume":"66","author":"Matsumoto","year":"1989","journal-title":"Immunology"},{"key":"10.1016\/j.bcmd.2017.04.008_bb0155","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2141.2009.07599.x","article-title":"The hypereosinophilic syndromes: current concepts and treatments","volume":"145","author":"Gleich","year":"2009","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2017.04.008_bb0160","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1056\/NEJMoa0805435","article-title":"Mepolizumab for prednisone-dependent asthma with sputum eosinophilia","volume":"360","author":"Nair","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2017.04.008_bb0165","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1517\/13543780902922678","article-title":"Mepolizumab for difficult-to-control asthma with persistent sputum eosinophilia","volume":"18","author":"a Antoniu","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.bcmd.2017.04.008_bb0170","article-title":"Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis","volume":"14","author":"Laurence","year":"2016","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"10.1016\/j.bcmd.2017.04.008_bb0175","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood.V118.21.4666.4666","article-title":"Use of anti-C5 monoclonal antibody eculizumab in the treatment of a patient with refractory idiopathic Thrombotic Thrombocytopenic Purpura (TTP)","volume":"118","author":"Chapin","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bcmd.2017.04.008_bb0180","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/bjh.12387","article-title":"Use of eculizumab in the treatment of a case of refractory, ADAMTS13\u2010deficient thrombotic thrombocytopenic purpura: additional data and clinical follow\u2010up","volume":"162","author":"Tsai","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2017.04.008_bb0185","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/j.1365-2141.2012.09084.x","article-title":"Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura","volume":"157","author":"Chapin","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2017.04.008_bb0190","series-title":"Methods in Cell Biology","author":"Gorczyca","year":"2011"},{"key":"10.1016\/j.bcmd.2017.04.008_bb0195","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1006\/bbrc.1998.9645","article-title":"Cloning and tissue distribution of a novel serine protease esp-1 from human eosinophils","volume":"252","author":"Inoue","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcmd.2017.04.008_bb0200","series-title":"Renal Involvement in Idiopathic Hypereosinophic Syndrome","author":"Shehwaro","year":"2013"},{"key":"10.1016\/j.bcmd.2017.04.008_bb0205","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2169\/internalmedicine.48.2282","article-title":"Thrombotic thrombocytopenic purpura complicated with Hypereosinophilic syndrome","volume":"48","author":"Ohguchi","year":"2009","journal-title":"Intern. Med."},{"key":"10.1016\/j.bcmd.2017.04.008_bb0210","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000001943","article-title":"Eosinophilic granulomatosis with polyangiitis with thrombotic microangiopathy: is simultaneous systemic lupus erythematosus associated with clinical manifestations?: a case report and review of the literature","volume":"94","author":"Fukui","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bcmd.2017.04.008_bb0215","series-title":"Allergen-specific Ige and Blood Eosinophils in Food Allergy","author":"Pien","year":"2007"}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107997961730075X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107997961730075X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:34:29Z","timestamp":1761050069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107997961730075X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":43,"alternative-id":["S107997961730075X"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2017.04.008","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resolution of a steroid-resistant, hypereosinophilic immune diathesis with mepolizumab and concomitant amelioration of a mixed thrombotic microangiopathy","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2017.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}